Kura Oncology (NASDAQ:KURA) Shares Gap Up After Strong Earnings

Kura Oncology, Inc. (NASDAQ:KURA) shares gapped up prior to trading on Thursday following a better than expected earnings announcement. The stock had previously closed at $9.94, but opened at $10.61. Kura Oncology shares last traded at $11.1790, with a volume of 1,178,828 shares changing hands.

The company reported ($0.77) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.11. Kura Oncology had a negative net margin of 411.19% and a negative return on equity of 141.95%. The company had revenue of $20.87 million for the quarter, compared to analyst estimates of $20.16 million.

Kura Oncology News Roundup

Here are the key news stories impacting Kura Oncology this week:

• Positive Sentiment: KOMZIFTI momentum strengthened. The acute myeloid leukemia treatment generated $9.1 million in net product revenue, a 57% increase from the first quarter, while new patient starts rose 35% to approximately 115. This commercial growth suggests increasing adoption of Kura’s marketed product. Kura Oncology Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Financial results exceeded expectations. Kura reported a second-quarter loss of $0.77 per share, narrower than the $0.88–$0.89 analyst consensus, while revenue of $20.87 million topped expectations of approximately $20.16 million. The earnings beat may be contributing to the stock’s strength. Kura Oncology Reports Q2 Loss and Beats Revenue Estimates
• Positive Sentiment: Collaboration revenue is expected to provide additional support. Management outlined approximately $90 million to $110 million of collaboration revenue for 2027, improving the company’s medium-term financial visibility. Kura Outlines 2027 Collaboration Revenue
• Neutral Sentiment: Clinical catalysts remain longer term. Kura is targeting topline results from the KOMET-017 study in 2028, leaving investors dependent on commercial execution and collaboration revenue in the nearer term. Kura Oncology Q2 2026 Earnings Call Transcript
• Negative Sentiment: Kura remains deeply unprofitable. Despite beating estimates, the company posted a substantial quarterly loss, with a reported negative net margin of 411.19%. Continued operating losses could limit valuation upside until product and collaboration revenue scale further. Kura Oncology Q2 2026 Earnings Call Summary

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. Wedbush upped their target price on Kura Oncology from $36.00 to $38.00 and gave the company an “outperform” rating in a report on Thursday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kura Oncology in a research report on Friday, July 17th. CLSA set a $24.00 price target on Kura Oncology in a report on Thursday, June 4th. Oppenheimer set a $24.00 price objective on Kura Oncology in a research report on Thursday, May 28th. Finally, Sanford C. Bernstein set a $24.00 price objective on Kura Oncology in a research note on Monday, June 15th. Ten equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $25.62.

Insiders Place Their Bets

In other Kura Oncology news, insider Mollie Leoni sold 84,929 shares of the business’s stock in a transaction dated Thursday, June 18th. The shares were sold at an average price of $9.82, for a total value of $834,002.78. Following the transaction, the insider directly owned 182,345 shares in the company, valued at $1,790,627.90. The trade was a 31.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 7.60% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Kura Oncology

A number of hedge funds have recently modified their holdings of KURA. BlackRock Inc. purchased a new position in Kura Oncology in the 2nd quarter valued at approximately $115,286,000. State Street Corp lifted its position in shares of Kura Oncology by 47.5% during the fourth quarter. State Street Corp now owns 4,931,090 shares of the company’s stock worth $51,234,000 after acquiring an additional 1,587,959 shares in the last quarter. Jacobs Levy Equity Management Inc. lifted its position in shares of Kura Oncology by 101.6% during the third quarter. Jacobs Levy Equity Management Inc. now owns 2,224,590 shares of the company’s stock worth $19,688,000 after acquiring an additional 1,121,228 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Kura Oncology in the second quarter worth $10,927,000. Finally, Renaissance Technologies LLC boosted its holdings in shares of Kura Oncology by 111.6% in the fourth quarter. Renaissance Technologies LLC now owns 1,830,566 shares of the company’s stock worth $19,020,000 after acquiring an additional 965,256 shares during the period.

Kura Oncology Stock Performance

The company has a market capitalization of $980.55 million, a PE ratio of -3.30 and a beta of 0.38. The company has a quick ratio of 6.14, a current ratio of 6.15 and a debt-to-equity ratio of 0.09. The company has a 50-day moving average price of $10.15 and a two-hundred day moving average price of $9.31.

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.